Orally active insulin-like growth factor 1 receptor (IGF1R) inhibitor that exhibits no activity at the insulin receptor, FGFR, PDGFR or EGFR. Inhibits IGF1R autophosphorylation (IC50
~ 1 nM), increases the fraction of cells in the G2
/M phase and upregulates apoptosis. Exhibits antiproliferative effects in multiple cancer cell lines (IC50
= 0.05 - 15 μ
M), and has anticancer and antineovascularization activity in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells.
Stromberg et al.
Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor.
Economou et al.
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.
Girnita et al.
Cancer Res., 2004;64:236
The citations listed below are publications that use Tocris products. Selected citations for Picropodophyllotoxin include:
Showing Results 1 - 1 of 1